Conavi Medical to Participate in the MedInvest MedTech, AI & Digital Health Conference
Conavi Medical to Participate in the MedInvest MedTech, AI & Digital Health Conference
– Marks first time as a public company that Conavi is presenting at an investor event –
這是Conavi作爲一家上市公司第一次在投資者活動中進行展示
– Live webcast presentation on Wednesday, December 11th at 3:35 p.m. ET –
– 網絡直播演示將於12月11日星期三下午3:35(東部時間)進行 –
TORONTO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) ("Conavi Medical" or the "Company"), a commercial stage company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures, today announced that its Chief Executive Officer, Thomas Looby, will present an update on the Company's business at the MedInvest MedTech, AI & Digital Health Conference on Wednesday, December 11, 2024 at 3:35 p.m. Eastern Time in New York City.
多倫多,2024年12月10日(全球新聞網)—— Conavi醫療CORP(TSXV: CNVI)("Conavi醫療"或"公司"),是一家專注於設計、製造和營銷影像技術以指導常見的微創心血管手術的商業階段公司,今天宣佈首席執行官托馬斯·盧比(Thomas Looby)將在2024年12月11日東部時間下午3:35在紐約市的MedInvest MedTech,人工智能與互聯網醫療大會上介紹公司的業務更新。
The presentation will be broadcast live and archived on the Company's website at in the Investors section.
該演示將進行現場直播並在公司網站的投資者部分歸檔。
About Conavi Medical
關於康納維醫療
Conavi Medical is focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. Its patented Novasight Hybrid System is the first system to combine both intravascular ultrasound (IVUS) and optical coherence tomography (OCT) to enable simultaneous and co-registered imaging of coronary arteries. The Novasight Hybrid System has 510(k) clearance from the U.S. Food and Drug Administration; and regulatory approval for clinical use from Health Canada, China's National Medical Products Administration, and Japan's Ministry of Health, Labor and Welfare. For more information, visit .
Conavi Medical專注於設計、製造和營銷成像技術,以指導常見的微創心血管手術。其專利的Novasight混合系統是第一個結合了血管內超聲(IVUS)和光學相干斷層掃描(OCT)的系統,能夠同時和共配準成像冠狀動脈。Novasight混合系統已獲得美國食品和藥物管理局的510(k)許可;並獲得加拿大衛生部、中國國家藥品監督管理局和日本厚生勞動省的臨床使用監管批准。更多信息,請訪問。
Cautionary Statement Regarding Forward-Looking Information
關於前瞻性信息的警示聲明
This news release contains "forward-looking statements" within the meaning of applicable Canadian and U.S. securities laws, which reflect the current expectations of management of Conavi's future growth, results of operations, performance and business prospects and opportunities. Forward-looking statements are frequently, but not always, identified by words such as "may", "would", "could", "will", "anticipate", "believe", "plan", "expect", "intend", "estimate", "potential for" and similar expressions, although these words may not be present in all forward-looking statements. Forward-looking statements that appear in this release may include, without limitation, references to Conavi's plans for the commercialization of its Novasight Hybrid System.
本新聞稿包含適用的加拿大和美國證券法意義上的「前瞻性聲明」,反映了Conavi管理層對未來增長、運營成果、表現和業務前景及機會的當前期望。前瞻性聲明通常但並不總是通過「可能」、「將」、「可以」、「會」、「預計」、「相信」、「計劃」、「期待」、「打算」、「估計」、「潛在的」和類似表達來識別,儘管這些詞可能並不出現在所有的前瞻性聲明中。本聲明中出現的前瞻性聲明可能包括但不限於對Conavi實施其Novasight混合系統商業化計劃的參考。
These forward-looking statements reflect management's current beliefs with respect to future events, and are based on information currently available to management that, while considered reasonable by management as of the date on which the statements are made, are inherently subject to significant business, economic and competitive uncertainties and contingencies which could result in actions, events, conditions, results, performance or achievements to be materially different from those projected in the forward-looking statements. Forward-looking statements involve significant risks, uncertainties and assumptions and many factors could cause Conavi's actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements. Such factors and assumptions include, but are not limited to, Conavi's ability to retain key personnel; its ability to execute on its business plans and strategies; and other factors listed in the "Risk Factors" sections of the joint information circular of Conavi dated August 30, 2024 (which may be viewed at ). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements.
These forward-looking statements reflect management's current beliefs with respect to future events, and are based on information currently available to management that, while considered reasonable by management as of the date on which the statements are made, are inherently subject to significant business, economic and competitive uncertainties and contingencies which could result in actions, events, conditions, results, performance or achievements to be materially different from those projected in the forward-looking statements. Forward-looking statements involve significant risks, uncertainties and assumptions and many factors could cause Conavi's actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements. Such factors and assumptions include, but are not limited to, Conavi's ability to retain key personnel; its ability to execute on its business plans and strategies; and other factors listed in the "Risk Factors" sections of the joint information circular of Conavi dated August 30, 2024 (which may be viewed at ). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements.
Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions and Conavi has attempted to identify important factors that could cause actual actions, events, conditions, results, performance or achievements to differ materially from those described in forward-looking statements, Conavi cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. Except as required by law, Conavi expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. Accordingly, investors should not place undue reliance on forward-looking statements. All the forward-looking statements are expressly qualified by the foregoing cautionary statements.
Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions and Conavi has attempted to identify important factors that could cause actual actions, events, conditions, results, performance or achievements to differ materially from those described in forward-looking statements, Conavi cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. Except as required by law, Conavi expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. Accordingly, investors should not place undue reliance on forward-looking statements. All the forward-looking statements are expressly qualified by the foregoing cautionary statements.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
無論是TSX創業公司交易所還是其監管服務提供者(按TSX創業公司交易所政策中的定義)均不對本新聞稿的充足性或準確性承擔責任。
Contacts
聯繫人
Stephen Kilmer
Investor Relations
(647) 872-4849
stephen.kilmer@conavi.com
斯蒂芬·基爾默
投資者關係
(647) 872-4849
stephen.kilmer@conavi.com
Stefano Picone
Chief Financial Officer
(416) 483-0100
斯特凡諾·皮科內
首席財務官
(416) 483-0100